 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- | DS-7423 / Daiichi Sankyo
Preclinical, Journal: HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models. (Pubmed Central) - Apr 6, 2022
Concomitant targeting of PI3K/mTOR with either HER2 or mGluR1 inhibitors results in decreased cell survival and tumor growth in xenograft studies. Our results suggest a novel therapeutic possibility for PTEN wild-type-PI3K/AKT mutant prostate cancer patients based in the combination of PI3K/mTOR blockade with HER2 or mGluR1 inhibitors.
- | RG7112 / Roche, DS-7423 / Daiichi Sankyo
Journal, PARP Biomarker: Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma. (Pubmed Central) - Dec 6, 2019
Our results suggest a novel therapeutic possibility for PTEN wild-type-PI3K/AKT mutant prostate cancer patients based in the combination of PI3K/mTOR blockade with HER2 or mGluR1 inhibitors. A combination therapy targeting the PI3K pathway and MDM2 might be a promising therapeutic strategy in CCOC.
- | DS-7423 / Daiichi Sankyo
Biomarker, Journal: Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. (Pubmed Central) - Oct 12, 2017
Our present findings establish that DS can specifically be used in patients who have PI3K pathway activation and/or loss of PTEN function. Further studies are warranted to determine the potential of DS for glioma treatment.
- DS-7423 / Daiichi Sankyo
Enrollment change, Metastases: Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov) - Feb 23, 2014
P1, N=42, Completed, Sponsor: Daiichi Sankyo Inc.
Further studies are warranted to determine the potential of DS for glioma treatment. N=66 --> 42
- | DS-7423 / Daiichi Sankyo
Trial completion, Metastases: Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors (clinicaltrials.gov) - Feb 23, 2014
P1, N=42, Completed, Sponsor: Daiichi Sankyo Inc.
N=66 --> 42 Active, not recruiting --> Completed